Scientist, DMPK & BioA
Denali Therapeutics
South San Francisco, California
Manuel Montalban is a Scientist in the Bioanalytical group at Denali Therapeutics and manages the development and implementation of bioanalytical methods for biomarker analysis, pharmacokinetic evaluation, and immunogenicity assessment to progress large molecule therapeutic programs. Manuel has seven years of biopharmaceutical and biotechnology industry experience; currently with a focus on developing, qualifying, validating, and implementing bioanalytical methods for large molecules from research through Phase 2/3. Before joining Denali, Manuel led the biomarker assessment efforts in nonclinical and clinical development of large molecule programs at Alector (South San Francisco, USA). Before this, Manuel was a member of the Translational Science Biomarker group at Denali Therapeutics with a focus on assay development and understanding prognostic and predictive biomarkers. Manuel holds a B.S. in Molecular and Cellular Biology from Dominican University and is currently pursuing a M.S. in Biotechnology from the University of San Francisco.
Disclosure information not submitted.
An Innovative Approach to Quantifying a Serum Biomarker in the Presence of Endogenous Interferences
Tuesday, October 22, 2024
10:00 AM – 10:30 AM MT